A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Inclusion Criteria:

- Subjects must have genotype 1 Chronic Hepatitis C

- Subjects must have compensated cirrhosis

- Subjects may either be treatment naïve, or may have received a course of Peg IFN/RBV
without evidence of response. Subjects who are considered to be relapsers to Peg
IFN/RBV, or who are partial or null responders will be considered

- Subjects with hemophilia may be permitted to enroll with permission of the medical
monitor

Exclusion Criteria:

- Any previous treatment with an investigational drug or drug regimen for the treatment
of hepatitis C, or previous treatment with an approved protease inhibitor

- Any contraindication to Peg-IFN or RBV therapy

- Evidence of hepatic decompensation: history of ascites, hepatic encephalopathy, or
bleeding esophageal varices

- A history of acquired immunodeficiency infection, organ transplantation or have an
ongoing requirement for immunosuppressive medicines